Literature DB >> 8778601

Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network.

J M Drazen1, E Israel, H A Boushey, V M Chinchilli, J V Fahy, J E Fish, S C Lazarus, R F Lemanske, R J Martin, S P Peters, C Sorkness, S J Szefler.   

Abstract

BACKGROUND: Inhaled beta-agonists are the most commonly used treatment for asthma, but data suggest that regularly scheduled use of these agents may have deleterious effect on the control of asthma. We compared the effects of regularly scheduled use of inhaled albuterol with those of albuterol used only as needed in patients with mild chronic, stable asthma.
METHODS: In a multicenter, double-blind study, we randomly assigned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or only as needed (129 patients). The patients were followed for 16 weeks.
RESULTS: The primary outcome indicator, peak expiratory air flow measured in the morning, did not change significantly during the treatment period in the scheduled (416 liters per minute after the run-in period and 414 liters per minute after the treatment period) or the as-needed (424 liters per minute at both times) treatment groups (P=0.71). There were no significant differences between the two groups in peak flow variability, forced expiratory volume in one second, the number of puffs of supplemental albuterol needed, asthma symptoms, asthma quality-of-life score, or airway responsiveness to methacholine. The statistically significant differences between the groups in evening peak flow and in the short-term bronchodilator response to inhaled albuterol were small and judged to be clinically unimportant.
CONCLUSIONS: In patients with mild asthma, neither deleterious nor beneficial effects derived from the regular use of inhaled albuterol beyond those derived from use of the drug as needed. Inhaled albuterol should be prescribed for patients with mild asthma on an as-needed basis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8778601     DOI: 10.1056/NEJM199609193351202

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  57 in total

1.  Guidelines do matter.

Authors:  N Anthonisen
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

Review 2.  Review of psychosocial stress and asthma: an integrated biopsychosocial approach.

Authors:  R J Wright; M Rodriguez; S Cohen
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

3.  Chronic asthma.

Authors:  C Cates
Journal:  BMJ       Date:  2001-10-27

Review 4.  New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.

Authors:  J K L Walker; R B Penn; N A Hanania; B F Dickey; R A Bond
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 5.  Asthma treatment in the 21st century: what's next?

Authors:  Stephen P Peters
Journal:  Clin Rev Allergy Immunol       Date:  2004-12       Impact factor: 8.667

6.  The combined effects of zafirlukast, prednisone, and inhaled budesonide on IL-13 and IFN-gamma secretion.

Authors:  Fiona K Gibbons; Elliot Israel; Aaron Deykin; Bianca Schaub; Hong Z He; David L Perkins; Patricia W Finn
Journal:  J Clin Immunol       Date:  2005-09       Impact factor: 8.317

7.  beta-Adrenergic receptor polymorphisms and response to salmeterol.

Authors:  Michael E Wechsler; Erik Lehman; Stephen C Lazarus; Robert F Lemanske; Homer A Boushey; Aaron Deykin; John V Fahy; Christine A Sorkness; Vernon M Chinchilli; Timothy J Craig; Emily DiMango; Monica Kraft; Frank Leone; Richard J Martin; Stephen P Peters; Stanley J Szefler; Wenlei Liu; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2005-12-01       Impact factor: 21.405

8.  Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model.

Authors:  Long P Nguyen; Rui Lin; Sergio Parra; Ozozoma Omoluabi; Nicola A Hanania; Michael J Tuvim; Brian J Knoll; Burton F Dickey; Richard A Bond
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

Review 9.  Pharmacogenetics of asthma.

Authors:  John J Lima; Kathryn V Blake; Kelan G Tantisira; Scott T Weiss
Journal:  Curr Opin Pulm Med       Date:  2009-01       Impact factor: 3.155

Review 10.  Pharmacogenetics of the beta 2-adrenergic receptor gene.

Authors:  Victor E Ortega; Gregory A Hawkins; Stephen P Peters; Eugene R Bleecker
Journal:  Immunol Allergy Clin North Am       Date:  2007-11       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.